EBGLYSS Receives Positive CHMP Opinion for Moderate-to-Severe Atopic Dermatitis Almirall S.A. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment o...
Find MoreCutaneous T-cell lymphoma (CTCLs) characterized by cutaneous infiltration of malignant monoclonal T-lymphocytes is a rare lymphoma affecting around 6.4 cases per million individuals every year. The total incident population of Cutaneous T-cell lymphoma in the 7MM was around 7.5K in 2021, with the US accounting for ...
Find MoreCutaneous T-cell lymphomas (CTCLs) constitute a group of non-Hodgkin lymphomas of the skin. CTCL has an annual age-adjusted incidence of approximately 6 cases per million people. In the United States, approximately 1,000 new cases of skin lymphoma are diagnosed each year. CTCL affects males twice as females. Moreov...
Find MoreCutaneous T-cell lymphoma (CTCL) is a group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Cutaneous T-cell lymphoma can cause rash-like skin redness, slightly raised or scaly round patches on the skin, itchy skin, discoloured patches on the skin, enlarged ly...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.